Get the Stockscreener App
3.67
3.55%
-0.135
After Hours:
3.67
Titan Pharmaceuticals Inc De stock is traded at $3.67, with a volume of 3,366.
It is down -3.55% in the last 24 hours and down -23.38% over the past month.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$3.805
Open:
$3.75
24h Volume:
3,366
Relative Volume:
0.01
Market Cap:
$3.48M
Revenue:
$61,000
Net Income/Loss:
$-6.17M
P/E Ratio:
-6.4386
EPS:
-0.57
Net Cash Flow:
$-6.43M
1W Performance:
-15.83%
1M Performance:
-23.38%
6M Performance:
-42.11%
1Y Performance:
-46.03%
1-Day Range:
$3.67
$3.81
1-Week Range:
$3.67
$4.6594
52-Week Range:
$3.565
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals Inc De
Sector
Industry
Phone
(650) 244-4990
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Compare TTNP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TTNP | 3.67 | 3.48M | 61,000 | -6.17M | -6.43M | -0.57 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-19 | Initiated | Maxim Group | Buy |
| Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Stock (TTNP) Latest News
Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan
Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan
Elite Pharmaceuticals (ELTP) to Host Q2 FY2025 Earnings Call on November 15 | ELTP Stock News - StockTitan
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - StockTitan
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results - StockTitan
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - StockTitan
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - StockTitan
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - StockTitan
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - StockTitan
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - StockTitan
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - StockTitan
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - StockTitan
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - StockTitan
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - StockTitan
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support - StockTitan
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - StockTitan
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - StockTitan
Opioids Agonist Drugs Market Research Report 2024 -Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen P – IndiaPolitics.com - IndiaPolitics.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - StockTitan
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health - StockTitan
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):